Abata Therapeutics

Therapeutic Area Head - Clinical Development – Dermatology

Remote

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries

Requirements

Candidates should possess a Ph.D. or M.D. in dermatology, immunology, or a related scientific field, with a strong understanding of dermatological conditions and treatment strategies. Demonstrated experience in clinical development, particularly in later-stage clinical trials (Phase 2 and beyond), is required. Expertise in dermatology and/or immunology is essential, along with effective collaborative skills and experience working across various phases of clinical development.

Responsibilities

As the Therapeutic Area Head - Clinical Development, you will lead and mentor a team of Medical Directors and Clinical Scientists, developing and executing an integrated clinical development strategy and clinical trial programs in dermatology. You will provide clinical expertise, obtain scientific advisory input, work cross-functionally to develop clinical studies, lead clinical aspects of regulatory interactions, and partner with the clinical operations team. Additionally, you will oversee programs across the dermatology portfolio, build relationships with investigators, contribute to the scientific communication strategy, and participate in medical review of adverse events.

Skills

Clinical Development
Medical Leadership
Regulatory Strategy
Clinical Trial Design
Team Mentoring
External Scientific Advisory

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Key Metrics

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI